The high dose of Eli Lilly’s retatrutide led to an average 28.7% loss in body weight measured at 68 weeks. These Phase 3 results are the first from the experimental obesity drug’s broad clinical trial program, which is on track to yield seven data readouts in the coming year.
The post Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial appeared first on MedCity News.
